TABLE 1

Patient Characteristics

							%ID/g
Patient no.	Group	Age (y)	Sex	Type	Diameter (cm)	Volume (cm³)	Before	After	Δ%	Metastatic	Necrosis	M75	CD31
1	Sorafenib, 1 wk	59.4	F	Part clear cell RCC, part rhabdoid	6	98	0.010	0.009	−15.4	No	Yes	±/++	±/++
2	Sorafenib, 1 wk	74.4	F	Clear cell RCC	7.2	190	0.020	0.020	−1.9	Yes	No	++	++
3	Sorafenib, 1 wk	67.8	M	Clear cell RCC	10.4	193	0.002	0.002	−16.7	No	Yes	±/++	±/++
4	Sorafenib, 1 wk	58.9	F	Clear cell RCC	4.9	61	0.007	0.004	−47.1	No	No	±	++
5	Sorafenib, 1 wk	68.8	F	Clear cell RCC	12.8	1,043	0.005	0.005	9.1	Yes	Yes	++	++
6	Sorafenib, 4 wk	57.6	M	Part clear cell RCC, part papillary	17.6	1,178	0.004	0.002	−55.1	Yes	Yes	−	±
7	Sorafenib, 4 wk	52.1	F	Clear cell RCC	11.8	612	0.004	0.002	−45.6	No	No	++	±
				Clear cell RCC	9.4	219	0.014	0.005	−64.4
8	Sorafenib, 4 wk	50.2	M	Part clear cell RCC, part sarcomatoid	7.9	141	0.025	0.005	−79.4	Yes	No	++	±
9	Sorafenib, 4 wk	71.3	F	Clear cell RCC	7	118	0.017	0.010	−39.9	No	Yes	++	±
				Clear cell RCC	5.7	83	0.006	0.002	−65.6
10	Sorafenib, 4 wk	64.1	F	Chromophobe RCC	10.2	412	—*	—*	—*	Yes	Yes	−	++
11	Control	62.0	M	Clear cell RCC	6.6	141	0.015	NA	NA	No	Yes	+++	++
12	Control	63.3	F	Part clear cell RCC, part rhabdoid	8	288	0.025	NA	NA	Yes	Yes	++	++
13	Control	58.8	F	Clear cell RCC	6.4	79	0.018	NA	NA	Yes	Yes	±/++	±
14	Control	69.7	F	Clear cell RCC	11.1	384	0.017	NA	NA	No	Yes	+++	++
15	Control	57.1	M	Papillary RCC (type 2)	7.8	196	0.003	NA	NA	No	Yes	+	+

*Physiologic uptake.
NA = not applicable.